promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i
![ProMIS Neurosciences logo](/files/LOGO/1374339-PMN.png)
Company profile
Ticker
PMN
Exchange
Website
CEO
Elliot Goldstein
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMORFIX LIFE SCIENCES LTD
SEC CIK
Corporate docs
Subsidiaries
ProMIS Neurosciences (US), Inc. ...
PMN stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
14 May 24
8-K
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
30 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
1 Apr 24
Latest ownership filings
SC 13G/A
SPHERA FUNDS MANAGEMENT LTD.
5 Feb 24
4
Neil K Warma
5 Jan 24
SC 13G/A
Sclar Jeremy M.
2 Jan 24
4
Jeremy M. Sclar
2 Jan 24
SC 13G/A
GORDON MICHAEL S
27 Dec 23
3
19 Promis Title
27 Dec 23
3
MICHAEL S GORDON
27 Dec 23
4
Gavin T. Malenfant
30 Oct 23
4
Johanne Kaplan
30 Oct 23
4
LARRY DOUGLAS ALTSTIEL
30 Oct 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.50 mm | 2.50 mm | 2.50 mm | 2.50 mm | 2.50 mm | 2.50 mm |
Cash burn (monthly) | 3.37 mm | 69.57 k | 1.23 mm | 1.08 mm | 3.43 mm | 1.55 mm |
Cash used (since last report) | 9.93 mm | 205.25 k | 3.62 mm | 3.19 mm | 10.12 mm | 4.57 mm |
Cash remaining | -7.44 mm | 2.29 mm | -1.12 mm | -691.57 k | -7.62 mm | -2.07 mm |
Runway (months of cash) | -2.2 | 32.9 | -0.9 | -0.6 | -2.2 | -1.3 |
Institutional ownership, Q4 2023
19.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 14 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.56 mm |
Total shares | 3.73 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Gordon Michael S | 2.49 mm | $0.00 |
Sclar Jeremy M. | 1.24 mm | $2.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Neil K Warma | Option Common Shares | Grant | Acquire A | No | No | 1.17 | 200,000 | 234.00 k | 208,333 |
4 Dec 23 | Sclar Jeremy M. | Series 2 Preferred Shares, no par value Common Stock | Buy | Acquire P | Yes | No | 0 | 150,000 | 0.00 | 150,000 |
4 Dec 23 | Sclar Jeremy M. | Series 1 Preferred Shares, no par value Common Stock | Sell | Dispose S | Yes | No | 0 | 150,000 | 0.00 | 0 |
4 Dec 23 | Sclar Jeremy M. | Series 2 Preferred Shares, no par value Common Stock | Buy | Acquire P | Yes | No | 0 | 150,000 | 0.00 | 150,000 |
4 Dec 23 | Sclar Jeremy M. | Series 1 Preferred Shares, no par value Common Stock | Sell | Dispose S | Yes | No | 0 | 150,000 | 0.00 | 0 |
26 Oct 23 | Geffken Daniel E. | Option Common Shares | Grant | Acquire A | No | No | 1.87 | 2,500 | 4.68 k | 2,500 |
11 Oct 22 | Sclar Jeremy M. | Warrants to Purchase Common Shares, no par value Common Stock | Buy | Acquire P | Yes | No | 0 | 26,217 | 0.00 | 26,217 |
News
ProMIS Neurosciences Q1 2024 Adj EPS $(0.19) Beats $(0.20) Estimate
14 May 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
15 Apr 24
ProMIS Neurosciences Q4 EPS $(0.09) Beats $(0.17) Estimate
2 Apr 24
Press releases
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
14 May 24
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
30 Apr 24
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
9 Apr 24
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
4 Apr 24
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
1 Apr 24